Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • News
    • Gastroenterology
    • Hemospray stops GI...

    Hemospray stops GI bleeding in 95% of patients within five minutes

    Written by Medha Baranwal Baranwal Published On 2018-05-09T19:15:53+05:30  |  Updated On 9 May 2018 7:15 PM IST
    Hemospray stops GI bleeding in 95% of patients within five minutes

    The U.S. Food and Drug Administration (FDA) has authorized the marketing of a new device called Hemospray which is used for the treatment of certain types of gastrointestinal bleeding. The FDA permitted marketing of the Hemospray device to the medical device company Wilson-Cook Medical Inc.


    Gastrointestinal bleeding is all types of bleeding that occurs in gastrointestinal (GI) tract including the esophagus, stomach or small intestine (upper GI tract) or colon and rectum (lower GI tract). Its causes include artery or vein (arteriovenous) malformations, gastric ulcers, cancer or inflammatory bowel disease, and diverticulosis. In older patients, there is a higher risk of death from GI bleeding.


    The Hemospray device is intended to treat most types of upper or lower GI bleeding and can cover large ulcers or tumors. The device is an aerosolized spray that delivers a mineral blend to the bleeding site through an endoscopic procedure. When the mineral blend comes in contact with the blood, it absorbs water and forms a gel that covers the bleeding site. It is not intended for use in patients with variceal bleeding, bleeding that comes from enlarged veins that develop in certain medical conditions like alcoholic liver disease. It is a nonthermal, nontraumatic treatment modality for achieving hemostasis.


    “The device provides an additional, non-surgical option for treating upper and lower GI bleeding in certain patients, and may help reduce the risk of death from a GI bleed for many patients,” said Binita Ashar, M.D., director, division of surgical devices, in the FDA’s Center for Devices and Radiological Health.


    For the purpose, the FDA reviewed data from clinical studies consisting of 228 patients with upper and lower GI bleeding, supplemented with real-world evidence from medical literature reports including an additional 522 patients.


    Based on the review the FDA made following inferences:




    • the device stopped GI bleeding in 95 percent of patients within five minutes of its usage

    • re-bleeding, usually within 72 hours, but up to 30 days following device usage, was observed in 20 percent of these patients

    • one serious side effect, bowel perforation, was observed in approximately 1 percent of patients

    • Hemospray is contraindicated in patients who have a gastrointestinal fistula are at high risk for experiencing a gastrointestinal perforation


    The Hemospray device was reviewed by FDA through the De Novo premarket review pathway, a regulatory pathway for some low to moderate risk devices of a new type.


    According to information from Wilson-Cook Medical, Hemospray "contains no human or animal proteins or botanicals and has no known allergens. Hemospray is metabolically inert and deemed nontoxic, systemically or otherwise."

    Binita AsharDe Novo premarket reviewFDAgastrointestinal bleedinggastrointestinal tractGI bleedingGI tractHemosprayHemospray devicehemostasismarketing approvalmarketing of Hemospraymarketing of medical devicesmedical devicesU.S. Food and Drug AdministrationWilson-Cook Medical

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medha Baranwal Baranwal
    Medha Baranwal Baranwal
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok